NZYM B Novozymes A/S Class B

Novozymes launches new biosolution to redefine the plant-based meat experience by enhancing texture and encouraging more consumers to choose plant-based alternatives

Novozymes launches new biosolution to redefine the plant-based meat experience by enhancing texture and encouraging more consumers to choose plant-based alternatives

Novozymes is excited to offer Vertera® ProBite as a game-changing solution to the plant-based meat industry, opening up new possibilities to create today's and tomorrow's plant-based meat products with advanced texture and consumer-friendly labels. The new product is a part of Novozymes’ commitment to driving innovation in biosolutions and promoting sustainable food choices.

Copenhagen – September 28: Today marks an important milestone in the evolution of plant-based meat innovation with the launch of Vertera® ProBite, a solution set to advance the plant-based meat industry by changing the need for manufacturers’ use of unwanted texturizers to a natural alternative. Developed by global biosolutions provider, Novozymes, Vertera® ProBite will address and resolve the primary consumer concerns of texture and long ingredient lists and encourage more individuals to make the switch from traditional meat to plant-based alternatives.

"This product launch represents a significant milestone in the plant-based meat sector. Vertera® ProBite has the potential to redefine the consumer experience by improving the texture issue and at the same time enable a more consumer-friendly label. Two areas which are still hindering the widespread adoption of plant-based alternatives," said Birgitte Schou Borch, Head of the Plant & Food Business, Novozymes. 

Vertera® ProBite is an innovation based on the enzyme MTGase (microbial transglutaminase E.C. 2.3.2.13), designed to enhance the texture of plant-based products. Unlike previous solutions, Vertera® ProBite offers the unique advantage of requiring no labeling, marking a significant breakthrough for the plant-based meat industry.

The key features of Vertera® ProBite include:

  • Texture Enhancement: Vertera® ProBite has been specifically engineered to address the texture issue in plant-based meat products. It delivers an exceptional mouthfeel and consistency, ensuring a more satisfying culinary experience for consumers.
  • Simple label: Vertera® ProBite is approved as a processing aid, with its technological function fully realized during the food processing stage. This innovative approach means that any unintentional but technically unavoidable presence of the enzyme in the final product does not necessitate labeling, which will eliminate potential barriers to market entry by offering transparency and simplicity to consumers and enable to elimination of unwanted texturizers.
  • Ease of Handling: Vertera® ProBite is a liquid product, making it incredibly easy to dose and handle safely during food production. Its user-friendly nature is a boon for food manufacturers seeking efficiency in their operations.

Novozymes is committed to driving innovation in biosolutions and promoting sustainable food choices. Vertera® ProBite is another testament to the company's dedication to making the transition to plant-based diets more accessible and enjoyable for consumers worldwide.

About Novozymes

Novozymes is the world leader in biological solutions. Together with customers, partners, and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel, and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow.

 

 NASDAQ OMX: NZYM-B • 6,500 employees • DKK 15 billion turnover • 30+ industries • 700+ products



Media Relations  
Lina Danstrup

Head of External Communications

Phone:





 
 
   
Investor Relations  
Tobias Cornelius Björklund

Head of Investor Relations

Phone:

 

Attachment



EN
28/09/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE

Novonesis delivered 9% organic sales growth in H1 and full-year outloo...

Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8% COPENHAGEN, Denmark – August 21, 2025. Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%. Ester Baiget, President & CEO: “I’m very pleased with 9% organic sales growth in the first half of the year. Demand for our biosolutions is strong, and consequently, we are lifting the lower end of our full-year guidance to 6-8% organic sales growth. Our profitability also remains solid, despite strong headwinds from currencies. With a strong foundation in place, ...

 PRESS RELEASE

Interim report H1 2025

Interim report H1 2025 9% organic sales growth in H1 and FY outlook range narrowed to 6-8% Ester Baiget, President & CEO: “I’m very pleased with 9% organic sales growth in the first half of the year. Demand for our biosolutions is strong, and consequently, we are lifting the lower end of our full-year guidance to 6-8% organic sales growth.  Our profitability also remains solid, despite strong headwinds from currencies. With a robust foundation in place, we are well positioned to accelerate into our next strategy period until 2030, where we will continue to significantly invest in what mak...

 PRESS RELEASE

2030 financial targets announced: Organic sales growth acceleration, m...

2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement COPENHAGEN, Denmark - August 20, 2025. Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re-investments to secure long-term growth. By 2030, the company expects to deliver an organic sales CAGR of 6-9%, an adjusted EBITDA margin of ~39% and an adjusted ROIC excl. goodwill of ~16%. Novonesis is well positioned to continue to drive strong performance in biosolutions. The...

 PRESS RELEASE

2030 financial targets announced: Organic sales growth acceleration, m...

2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re-investments to secure long-term growth. By 2030, the company expects to deliver an organic sales CAGR of 6-9%, an adjusted EBITDA margin of ~39% and an adjusted ROIC excl. goodwill of ~16%. Novonesis is well positioned to continue to drive strong performance in biosolutions. The company is present across multiple end...

 PRESS RELEASE

Major shareholder announcement

Major shareholder announcement Please read the full announcement in PDF. Attachments

ResearchPool Subscriptions

Get the most out of your insights

Get in touch